5P1 Stock Chart & Stats
€13.05
-€0.04(-0.42%)
At close: 4:00 PM EST
€13.05
-€0.04(-0.42%)
Day’s Range― - ―
52-Week Range€11.50 - €14.00
Previous CloseN/A
Volume0.00
Average Volume (3M)99.00
Market Cap
€226.27M
Enterprise Value€225.13M
Total Cash (Recent Filing)€23.03M
Total Debt (Recent Filing)€16.28M
Price to Earnings (P/E)13.6
Beta0.25
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.98
Shares Outstanding17,036,577
10 Day Avg. Volume157
30 Day Avg. Volume99
Financial Highlights & Ratios
PEG Ratio0.25
Price to Book (P/B)163.15
Price to Sales (P/S)89.18
P/FCF Ratio1.24K
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.16
Revenue Forecast (FY)€270.70M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetBeing effectively debt-free in 2025 materially strengthens financial resilience and optionality. With no interest burden the company can redirect cash to R&D, working capital, dividends or bolt-on M&A, and better withstand sector downturns without refinancing risk, supporting durable capital flexibility.
Consistent Revenue GrowthMulti-year revenue growth indicates sustained demand for orthopedic and rehabilitation products and stable distribution channels. Consistent top-line expansion supports scale advantages, repeat sales from clinical customers, and underpins the company's ability to invest in product and commercial capabilities over the medium term.
Improving Profitability And EquityMeaningful margin recovery and growing equity in 2025 point to improved operational execution and capital strength. Higher margins provide durable earnings power, support reinvestment and dividends, and the stronger equity base raises tolerance for strategic initiatives without immediate financing needs.
Bears Say
Uneven Cash ConversionWeaker cash conversion versus net income and a material FCF decline in 2025 signal working-capital or investment pressures. Persistent variability in cash generation constrains reliable funding for capex, dividends or M&A and raises execution risk in financing growth without eroding liquidity cushions.
Margin VolatilitySignificant swings in gross and operating margins reduce earnings predictability and imply sensitivity to input costs, pricing mix, or channel dynamics. Persistent margin volatility undermines forecasting, complicates long-term investment decisions, and increases the risk that profit improvements may be reversed by operational shocks.
Limited Return Expansion Without LeverageAn unlevered balance sheet reduces financial risk but limits the ability to amplify returns via low-cost debt. Future ROE and EPS growth will depend heavily on operational improvement and organic expansion, making execution and margin gains the primary lever to drive shareholder returns over time.
PRIM, S.A. News
5P1 FAQ
What was PRIM, S.A.’s price range in the past 12 months?
PRIM, S.A. lowest stock price was €11.50 and its highest was €14.00 in the past 12 months.
What is PRIM, S.A.’s market cap?
PRIM, S.A.’s market cap is €226.27M.
When is PRIM, S.A.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were PRIM, S.A.’s earnings last quarter?
Currently, no data Available
Is PRIM, S.A. overvalued?
According to Wall Street analysts PRIM, S.A.’s price is currently Overvalued.
Does PRIM, S.A. pay dividends?
PRIM, S.A. does not currently pay dividends.
What is PRIM, S.A.’s EPS estimate?
PRIM, S.A.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PRIM, S.A. have?
PRIM, S.A. has 17,036,577 shares outstanding.
What happened to PRIM, S.A.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of PRIM, S.A.?
Currently, no hedge funds are holding shares in DE:5P1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PRIM, S.A.
Prim, S.A., operating through its various affiliated entities, specializes in the conception, production, and sale of orthopedic solutions. These items are utilized across diverse fields such as physical therapy, aquatic therapies (like thalassotherapy and hydrotherapy), rehabilitation, spa facilities, elderly care, and a range of supportive techniques, reaching customers within Spain and across global borders. Furthermore, the company supplies specialized goods for neuro-trauma, cardiovascular health, neuromodulation, surgical suites, endosurgical procedures, cosmetic surgery, and ear, nose, and throat (ENT) specialties. Beyond its product offerings, Prim, S.A. is involved in overseeing wellness developments, including hotel properties, vacation resorts, and athletic clubs. The firm was established in 1870 and maintains its principal office in Móstoles, Spain.
Technical Analysis
Oryzon Genomics SA
―
Pharma Mar SA
―
Atrys Health SA
―
Labiana Health SA
―
Santa Ana Global Enterprises SA
―